Document is current
Any future updates will be listed below
-
Authors
Bayer, Karl Ulrich https://orcid.org/0000-0003-0893-2200
Giese, Karl Peter https://orcid.org/0000-0003-4503-7344
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01 NS081248)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01 NS118786)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01 AG067713)
- License Information
-
More Information
Article History
Received: 24 January 2024
Accepted: 17 October 2024
First Online: 18 November 2024
Competing interests
: K.U.B. is cofounder and board member of Neurexis Therapeutics, a company that seeks to develop a CaMKII inhibitor into a therapeutic drug for cerebral ischemia. K.P.G. declares no competing interests.
